Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivavotinib + Nivolumab in Advanced Solid Tumors
NCT02834247Phase 1Terminated
- Sponsor
- Calithera Biosciences
- Start
- Aug 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of mivavotinib in solid tumor (advanced stage), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Calithera Biosciences. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Aug 2016; status: terminated.
02
Drugs
mivavotinib
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02834247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834247.